Biovie Inc Stock Price, News & Analysis

BioVie (NASDAQ: BIVI) has released significant updates from its Phase 2 clinical trial regarding NE3107 for Alzheimer’s Disease (AD). The trial demonstrated that a vast majority of patients experienced notable improvements in daily abilities and cognition, with 82% of participants showing a decrease in ADAS-Cog12 scores (p=0.0046). Moreover, NE3107 treatment correlated with reductions in TNF-a, suggesting potential neuroinflammation benefits. No adverse events were reported, and the company plans to present detailed results at the upcoming CTAD 2022 Annual Conference.

BioVie Inc. (NASDAQ: BIVI) announced the issuance of a U.S. patent for terlipressin monotherapy to treat ascites patients without hepatorenal syndrome, restoring patent protection for BIV201 until 2036. This patent, along with global applications and Orphan drug designation, aims to secure long-term intellectual property. Currently, there are no FDA-approved drugs for ascites treatment, affecting approximately 20,000 U.S. patients annually. The company is conducting a Phase 2b trial to evaluate BIV201's efficacy, with results expected in early 2023.

BioVie Inc. (NASDAQ: BIVI) announced its management team's participation in the virtual B. Riley Securities’ Neuro & Ophthalmology Conference on April 27-28, 2022. CEO Cuong Do and CMO Joseph Palumbo will discuss the novel mechanism of action of NE3107, BioVie’s lead compound targeting Alzheimer’s and Parkinson’s diseases. The fireside chat is scheduled for April 28, 2022, at 1:30 PM ET. Additionally, BioVie is advancing its drug candidate BIV201 for liver disease, with anticipated Phase 2 study results expected in early 2023.

BioVie Inc. (NASDAQ: BIVI) will feature an interview with President and CEO Cuong Do on The RedChip Money Report® airing March 12 at 7 p.m. ET on Bloomberg TV, reaching approximately 73 million households. BioVie is focused on developing therapies for advanced liver disease and neurodegenerative disorders. The company's key candidates include BIV201, which is currently in a US Phase 2 study for refractory ascites, and NE3107, undergoing a Phase 3 trial for mild to moderate Alzheimer's disease, with results expected in early 2023.

BioVie, a clinical-stage company listed on NASDAQ under the stock symbol BIVI, announced its participation in the Oppenheimer Virtual Annual Healthcare Conference from March 15-17, 2022. The presentation is scheduled for March 17 at 12:40 PM ET. BioVie is focused on innovative therapies for advanced liver disease and neurodegenerative disorders. Its candidate BIV201 is in a Phase 2 study targeting refractory ascites due to liver cirrhosis, with results expected in mid-2022. Additionally, NE3107 is in trials for Alzheimer’s and Parkinson’s diseases, aiming for primary completion in early 2023.

BioVie Inc. (NASDAQ: BIVI) has initiated the treatment of its first patient in a Phase 2 clinical trial (NM201) investigating the effects of NE3107 on Parkinson’s disease. This double-blind placebo-controlled study aims to evaluate safety, tolerability, and pharmacokinetics in 40 patients. NE3107 previously demonstrated promising effects in preclinical studies, improving motor symptoms and reducing L-dopa induced dyskinesia. Results are expected by mid-2022, with the trial being a significant milestone for the company's development pipeline in neurodegenerative diseases.

BioVie Inc. (NASDAQ: BIVI) announced its management team's participation in the LifeSci Partners 11th Annual Corporate Access Event, scheduled for January 5-7, 2022. The panel, titled "Defining Yourself When You Fit Into More Than One Basket," will take place on January 7, 2022, at 10:00 AM ET.

BioVie is focused on developing innovative therapies for advanced liver disease and neurodegenerative disorders. Its key candidates include BIV201 for liver cirrhosis and NE3107 for Alzheimer's, with ongoing trials aimed at addressing significant unmet medical needs.

BioVie Inc. (NASDAQ: BIVI) is launching a campaign with the American Liver Foundation to enhance awareness about liver cirrhosis and its complications, specifically refractory ascites. This initiative coincides with BioVie’s Phase 2b clinical trial of BIV201, a continuous infusion of terlipressin, aimed at treating this condition. Approximately 20,000 Americans suffer from refractory ascites, with a one-year survival rate of only 50%. The trial is being conducted at ten research centers in the U.S., and positive results could lead to a pivotal Phase 3 study commencing in 2022.

BioVie Inc. (NASDAQ: BIVI) announced a new debt facility with Avenue Venture Funds, providing up to $25 million, with an initial funding of $15 million on November 30, 2021. This funding aims to support key clinical milestones in 2022, including top-line data from trials of BIV201 in refractory ascites and NE3107 in Alzheimer’s. The company anticipates initiating a Phase 2 trial of NE3107 for Parkinson's disease and a Phase 3 trial for BIV201 for hepatorenal syndrome-acute kidney injury. This non-dilutive financing positions BioVie to advance innovative therapies for unmet medical needs.